Wait, we have a special offer for you! ✋

Get your exclusive discount now

Use FY25SAVE to get flat 20% off on the report No, I'd pay the full price

Terms & Conditions : This coupon is vaild exclusively for Global Market Reports 2025 and can be used Until March 31 , 2025 .

Global Sotrovimab Or Xevudy Market Report 2025

Sotrovimab Or Xevudy Market Report 2025: Epidemiology, Pipeline Analysis, Market Size, Trends, And Global Forecast 2034 – By Indication (COVID-19 Early Treatment, Post-Exposure Prophylaxis), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Pediatric, Adult, Geriatric)

Sotrovimab Or Xevudy Global Market Report 2025

Report Price : $4490.00 | Pages : | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Sotrovimab Or Xevudy Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Sotrovimab Or Xevudy Market Definition

Sotrovimab (Xevudy) is a monoclonal antibody treatment developed for the management of COVID-19. It is specifically designed to target the SARS-CoV-2 spike protein, preventing the virus from entering and infecting human cells. Sotrovimab is used for treating mild-to-moderate COVID-19 in patients at high risk of progressing to severe illness, offering an effective therapeutic option in early-stage infections.

The main indication for sotrovimab or xevudy is COVID-19 early treatment and post-exposure prophylaxis. The COVID-19 early treatment refers to the use of sotrovimab (xevudy) to treat patients who are diagnosed with COVID-19 early in the course of the disease. This treatment is designed to reduce the severity of symptoms, prevent complications, and decrease the likelihood of hospitalization, particularly in individuals who are at high risk of severe disease. It is distributed through various channels such as hospitals pharmacies, retail pharmacies, and online pharmacies and is utilized by pediatric, adult, and geriatric.

Sotrovimab Or Xevudy Market Segmentation

The sotrovimab or xevudy market covered in this report is segmented –

1) By Indication: COVID-19 Early Treatment; Post-Exposure Prophylaxis

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

3) By End User: Pediatric; Adult; Geriatric

Sotrovimab Or Xevudy Market Size and growth rate 2025 to 2029: Graph

Sotrovimab Or Xevudy Market Size 2025 And Growth Rate

The sotrovimab or xevudy market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to rise in prevalence of COVID-19, the increase in demand for effective monoclonal antibody treatments, growth in awareness of high-risk patient care, rise in government funding, and rise in collaborations between pharmaceutical companies.

Sotrovimab Or Xevudy Market Growth Forecast

The sotrovimab or xevudy market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to rising emergence of new COVID-19 variants, increasing focus on monoclonal antibody therapies, expanding healthcare access in developing regions, rising government support for pandemic preparedness, and growing telehealth services for treatment delivery. Major trends in the forecast period include advancements in vaccine manufacturing technologies, innovation in formulations, integration of telehealth, advancements in antibody production technologies, and advancements in antibody engineering.

Book your 30 minutes free consultation with our research experts

Contact Us

Sotrovimab Or Xevudy Market Driver: Impact Of Rising COVID-19 Cases On Market Growth

The rise in the prevalence of COVID-19 cases is expected to drive the growth of the sotrovimab or xevudy market going forward. COVID-19 is a disease caused by the SARS-CoV-2 virus, spreading through respiratory droplets and causing symptoms from mild fever to severe respiratory issues. Vaccines and hygiene practices help prevent its spread. COVID-19 cases are increasing due to factors such as new variants, reduced immunity, eased restrictions, seasonal indoor gatherings, and uneven vaccine coverage. Sotrovimab treats high-risk COVID-19 patients by neutralizing the virus early, preventing severe outcomes such as hospitalization or death. For instance, in March 2023, according to a report published by the Office for National Statistics, a UK-based government department for official statistics, as of March 2023, an estimated 1.9 million people in the UK (2.9% of the population) reported COVID. Most (92%) had COVID-19 over 12 weeks earlier, with 69% experiencing symptoms for over a year and 41% for over two years. Therefore, the rise in the prevalence of COVID cases is going to drive the growth of the sotrovimab or xevudy market.

Sotrovimab Or Xevudy Market Driver: Rising Healthcare Investments Driving Growth In The Market

The rise in healthcare investments is expected to drive the growth of the sotrovimab or xevudy market going forward. Healthcare investments refers to the total amount spent on healthcare services, including medical treatments, medications, and hospital care, within a specific period. Healthcare investments is rising due to factors such as an aging population, increasing healthcare needs, advancements in medical technology, and rising prices for services and medications. Investments in healthcare boost sotrovimab (xevudy) by supporting R&D, expanding production, and improving access for high-risk patients through partnerships and distribution networks. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department for official statistics, total healthcare expenditure saw a 5.6% increase in nominal terms from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth observed in 2022. Therefore, the rise in healthcare investments will drive the growth of the sotrovimab or xevudy market.

Global Sotrovimab Or Xevudy Market Major Players

Major companies operating in the sotrovimab or xevudy market are GSK plc; Vir Biotechnology Inc.

Global Sotrovimab Or Xevudy Market Trend: Strategic Partnerships and Production Expansion in the COVID-19 Treatment Market

The key trend in the sotrovimab or xevudy market is the emphasis on strategic investments to boost research and development, expand production capacities, and improve access to the drug. These partnerships are crucial for accelerating distribution and ensuring broader availability, especially in high-need regions. For instance, in January 2022, GSK plc, a UK-based pharmaceutical company, partnered with Vir Biotechnology Inc., a US-based biotechnology company, and announced a significant agreement with the United States government to purchase additional supplies of sotrovimab, a monoclonal antibody authorized for the early treatment of COVID-19. This agreement highlights the ongoing need for effective treatments as the pandemic continues to evolve. Sotrovimab is specifically designed for adults and adolescents at high risk of progressing to severe COVID-19, offering a vital option for those who do not require oxygen supplementation. This recent agreement reflects GSK and Vir's broader strategy to ensure that sotrovimab remains accessible despite the emergence of new variants of the virus.

Regional Analysis For The Global Sotrovimab Or Xevudy Market

North America was the largest region in the sotrovimab or xevudy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the sotrovimab or xevudy market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Sotrovimab Or Xevudy Market?

The sotrovimab or xevudy market consists of sales of pre-filled syringes and infusion kits. Values in this market are ‘factory gate’ values, representing the value of vaccines sold directly by manufacturers, either to governments, healthcare organizations, or distribution networks. This includes revenues from related services but excludes resales further along the supply chain or integration into other healthcare products.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Sotrovimab Or Xevudy Industry?

The sotrovimab or xevudy market research report is one of a series of new reports from The Business Research Company that provides sotrovimab or xevudy market statistics, including the sotrovimab or xevudy industry's global market size, regional shares, competitors with a sotrovimab or xevudy market share, detailed sotrovimab or xevudy market segments, market trends and opportunities, and any further data you may need to thrive in the sotrovimab or xevudy industry. This sotrovimab or xevudy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Sotrovimab Or Xevudy Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 Included ?
Revenue Forecast In 2034 Included ?
Growth Rate Included ?
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The sotrovimab or xevudy market covered in this report is segmented –
1) By Indication: COVID-19 Early Treatment; Post-Exposure Prophylaxis
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Pediatric; Adult; Geriatric
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled GSK plc; Vir Biotechnology Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Sotrovimab Or Xevudy Market Characteristics

    3. Sotrovimab Or Xevudy Market Biologic Drug Characteristics

    3.1. Molecule Type

    3.2. Route Of Administration (ROA)

    3.3. Mechanism Of Action (MOA)

    3.4. Safety And Efficacy

    4. Sotrovimab Or Xevudy Market Trends And Strategies

    5. Sotrovimab Or Xevudy Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

    6. Global Sotrovimab Or Xevudy Growth Analysis And Strategic Analysis Framework

    6.1. Global Sotrovimab Or Xevudy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    6.2. Analysis Of End Use Industries

    6.3. Global Sotrovimab Or Xevudy Market Growth Rate Analysis

    6.4. Global Sotrovimab Or Xevudy Historic Market Size and Growth, 2019 - 2024, Value ($ Million)

    6.5. Global Sotrovimab Or Xevudy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Million)

    6.6. Global Sotrovimab Or Xevudy Total Addressable Market (TAM)

    7. Global Sotrovimab Or Xevudy Pricing Analysis & Forecasts

    8. Sotrovimab Or Xevudy Market Segmentation

    8.1. Global Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    COVID-19 Early Treatment

    Post-Exposure Prophylaxis

    8.2. Global Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    Hospital Pharmacies

    Retail Pharmacies

    Online Pharmacies

    8.3. Global Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    Pediatric

    Adult

    Geriatric

    9. Global Sotrovimab Or Xevudy Epidemiology Of Clinical Indications

    9.1. Drug Side Effects

    9.2. Incidence And Prevalence of Clinical Indications

    10. Sotrovimab Or Xevudy Market Regional And Country Analysis

    10.1. Global Sotrovimab Or Xevudy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    10.2. Global Sotrovimab Or Xevudy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    11. Asia-Pacific Sotrovimab Or Xevudy Market

    11.1. Asia-Pacific Sotrovimab Or Xevudy Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    11.2. Asia-Pacific Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    11.3. Asia-Pacific Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    11.4. Asia-Pacific Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    12. China Sotrovimab Or Xevudy Market

    12.1. China Sotrovimab Or Xevudy Market Overview

    12.2. China Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

    12.3. China Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

    12.4. China Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

    13. India Sotrovimab Or Xevudy Market

    13.1. India Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    13.2. India Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    13.3. India Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    14. Japan Sotrovimab Or Xevudy Market

    14.1. Japan Sotrovimab Or Xevudy Market Overview

    14.2. Japan Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    14.3. Japan Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    14.4. Japan Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    15. Australia Sotrovimab Or Xevudy Market

    15.1. Australia Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    15.2. Australia Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    15.3. Australia Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    16. South Korea Sotrovimab Or Xevudy Market

    16.1. South Korea Sotrovimab Or Xevudy Market Overview

    16.2. South Korea Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    16.3. South Korea Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    16.4. South Korea Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    17. Western Europe Sotrovimab Or Xevudy Market

    17.1. Western Europe Sotrovimab Or Xevudy Market Overview

    17.2. Western Europe Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    17.3. Western Europe Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    17.4. Western Europe Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    18. UK Sotrovimab Or Xevudy Market

    18.1. UK Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    18.2. UK Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    18.3. UK Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    19. Germany Sotrovimab Or Xevudy Market

    19.1. Germany Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    19.2. Germany Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    19.3. Germany Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    20. France Sotrovimab Or Xevudy Market

    20.1. France Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    20.2. France Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    20.3. France Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    21. Eastern Europe Sotrovimab Or Xevudy Market

    21.1. Eastern Europe Sotrovimab Or Xevudy Market Overview

    21.2. Eastern Europe Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    21.3. Eastern Europe Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    21.4. Eastern Europe Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    22. North America Sotrovimab Or Xevudy Market

    22.1. North America Sotrovimab Or Xevudy Market Overview

    22.2. North America Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    22.3. North America Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    22.4. North America Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    23. USA Sotrovimab Or Xevudy Market

    23.1. USA Sotrovimab Or Xevudy Market Overview

    23.2. USA Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    23.3. USA Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    23.4. USA Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    24. Canada Sotrovimab Or Xevudy Market

    24.1. Canada Sotrovimab Or Xevudy Market Overview

    24.2. Canada Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    24.3. Canada Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    24.4. Canada Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    25. South America Sotrovimab Or Xevudy Market

    25.1. South America Sotrovimab Or Xevudy Market Overview

    25.2. South America Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    25.3. South America Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    25.4. South America Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    26. Middle East Sotrovimab Or Xevudy Market

    26.1. Middle East Sotrovimab Or Xevudy Market Overview

    26.2. Middle East Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    26.3. Middle East Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    26.4. Middle East Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    27. Africa Sotrovimab Or Xevudy Market

    27.1. Africa Sotrovimab Or Xevudy Market Overview

    27.2. Africa Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    27.3. Africa Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    27.4. Africa Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    28. Sotrovimab Or Xevudy Market Competitive Landscape And Company Profiles

    28.1. Sotrovimab Or Xevudy Market Competitive Landscape

    28.2. Sotrovimab Or Xevudy Market Company Profiles

    28.2.1. GSK plc Overview, Products and Services, Strategy and Financial Analysis

    28.2.2. Vir Biotechnology Inc. Overview, Products and Services, Strategy and Financial Analysis

    28.2.3. 0 Overview, Products and Services, Strategy and Financial Analysis

    28.2.4. 0 Overview, Products and Services, Strategy and Financial Analysis

    28.2.5. 0 Overview, Products and Services, Strategy and Financial Analysis

    29. Global Sotrovimab Or Xevudy Market Pipeline Analysis

    29.1. High Level Clinic Trail Information

    30. Global Sotrovimab Or Xevudy Market Competitive Benchmarking And Dashboard

    31. Key Mergers And Acquisitions In The Sotrovimab Or Xevudy Market

    32. Recent Developments In The Sotrovimab Or Xevudy Market

    33. Sotrovimab Or Xevudy Market High Potential Countries, Segments and Strategies

    33.1 Sotrovimab Or Xevudy Market In 2029 - Countries Offering Most New Opportunities

    33.2 Sotrovimab Or Xevudy Market In 2029 - Segments Offering Most New Opportunities

    33.3 Sotrovimab Or Xevudy Market In 2029 - Growth Strategies

    33.3.1 Market Trend Based Strategies

    33.3.2 Competitor Strategies

    34. Appendix

    34.1. Abbreviations

    34.2. Currencies

    34.3. Historic And Forecast Inflation Rates

    34.4. Research Inquiries

    34.5. The Business Research Company

    34.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Million
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Million
  • Table 3: Global Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 4: Global Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 5: Global Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 6: Global Sotrovimab Or Xevudy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 7: Global Sotrovimab Or Xevudy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 8: Asia-Pacific, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 9: Asia-Pacific, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 10: Asia-Pacific, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 11: China, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 12: China, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 13: China, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 14: India, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 15: India, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 16: India, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 17: Japan, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 18: Japan, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 19: Japan, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 20: Australia, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 21: Australia, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 22: Australia, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 23: South Korea, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 24: South Korea, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 25: South Korea, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 26: Western Europe, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 27: Western Europe, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 28: Western Europe, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 29: UK, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 30: UK, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 31: UK, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 32: Germany, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 33: Germany, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 34: Germany, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 35: France, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 36: France, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 37: France, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 38: Eastern Europe, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 39: Eastern Europe, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 40: Eastern Europe, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 41: North America, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 42: North America, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 43: North America, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 44: USA, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 45: USA, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 46: USA, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 47: Canada, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 48: Canada, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 49: Canada, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 50: South America, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 51: South America, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 52: South America, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 53: Middle East, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 54: Middle East, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 55: Middle East, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 56: Africa, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 57: Africa, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 58: Africa, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 59: GSK plc Financial Performance
  • Table 60: Vir Biotechnology Inc.  Financial Performance
  • Table 61: 0 Financial Performance
  • Table 62: 0 Financial Performance
  • Table 63: 0 Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Million
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Million
  • Figure 3: Global Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 4: Global Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 5: Global Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 6: Global Sotrovimab Or Xevudy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 7: Global Sotrovimab Or Xevudy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 8: Asia-Pacific, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 9: Asia-Pacific, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 10: Asia-Pacific, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 11: China, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 12: China, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 13: China, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 14: India, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 15: India, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 16: India, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 17: Japan, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 18: Japan, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 19: Japan, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 20: Australia, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 21: Australia, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 22: Australia, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 23: South Korea, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 24: South Korea, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 25: South Korea, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 26: Western Europe, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 27: Western Europe, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 28: Western Europe, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 29: UK, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 30: UK, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 31: UK, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 32: Germany, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 33: Germany, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 34: Germany, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 35: France, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 36: France, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 37: France, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 38: Eastern Europe, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 39: Eastern Europe, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 40: Eastern Europe, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 41: North America, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 42: North America, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 43: North America, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 44: USA, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 45: USA, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 46: USA, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 47: Canada, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 48: Canada, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 49: Canada, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 50: South America, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 51: South America, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 52: South America, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 53: Middle East, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 54: Middle East, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 55: Middle East, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 56: Africa, Sotrovimab Or Xevudy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 57: Africa, Sotrovimab Or Xevudy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 58: Africa, Sotrovimab Or Xevudy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 59: GSK plc Financial Performance
  • Figure 60: Vir Biotechnology Inc.  Financial Performance
  • Figure 61: 0 Financial Performance
  • Figure 62: 0 Financial Performance
  • Figure 63: 0 Financial Performance

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Read More

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

Read More

The Microbiome Market Share, Market Size, And Growth Rate 2022

Read More

Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company

Read More

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the hematology drugs market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the GI drugs market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the oral biologics and biosimilars market research report 2022 with industry size, share, segments and market growth

Read More

Antibody Drug Conjugates Global Market Report 2025 – By Type (Monoclonal Antibodies, Linker, Drug/Toxin, Other Types), By Product (Adcertis, Kadcyla, Other Products), By Technology (Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Other Technology), By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications), By End User (Hospital, Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Antibody Contract Manufacturing Global Market Report 2025 – By Product (Monoclonal Antibodies, Polyclonal Antibodies, Other Products), By Source (Mammalian, Microbial, Scale Of Operation (Preclinical, Clinical, Commercial), By End-User (Biopharmaceutical Companies, Research Laboratories, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Next-Generation Antibody Therapeutics Global Market Report 2025 – By Types Of Antibodies (Monoclonal Antibodies, Polyclonal Antibodies, Biospecific Antibodies, Antibody-Drug Conjugates, Other Types), By Therapeutic Area (Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas), By End-User (Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Antibody Discovery Global Market Report 2025 – By Methods (Phage Display, Hybridoma, Other Methods), By Antibody Type (Humanized Antibody, Human Antibody, Chimeric Antibody, Murine Antibody), By End Users (Pharmaceutical And Biotechnology Industry, Research Laboratory, Academic Laboratory) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Antivirus Software Global Market Report 2025 – By Type (Computers, Tablets, Smart Phones, Other Types), By Operating System (Windows, MAC, Android Or IOS Or Linux), By End User (Corporate, Personal, Government) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Virus Filtration Global Market Report 2025 – By Type( Kits And Reagents, Services, Filtration Systems, Other Types), By Application( Medical Devices, Water Purification, Air Purification, Biologicals, Vaccines And Therapeutics, Blood And Blood Products, Cellular And Gene Therapy Products, Other Applications), By End-User( Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, Medical Device Companies) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Herpes Simplex Virus Treatment Global Market Report 2025 – By Type (Herpes Simplex Virus-1 Infection, Herpes Simplex Virus-2 Infection), By Drug Type (Acyclovir, Valacyclovir, Famciclovir, Other Drugs), By Route Of Administration (Oral, Injection, Topical), By Vaccine (Simplirix, Other Vaccines), By Distribution Channel (Hospital Pharmacies, Drug store, Retail Pharmacies, Online Providers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Coronavirus (COVID-19) Current Therapy Market 2025 – By Drug Type (Antivirals, Monoclonal Antibodies (Mabs), Corticosteroid, Supplements, Antimalarial, Interferons And Interleukin Inhibitors, Other Anti Infections, Others), By Route Of Administration (Oral, Intravenous), By End User (Hospitals, Clinics, Home Care, Other End Users), And By Region, Opportunities And Strategies – Global Forecast To 2035

View Report

Frequently Asked Questions

What is the definition of the Sotrovimab Or Xevudy market?

Sotrovimab (Xevudy) is a monoclonal antibody treatment developed for the management of COVID-19. It is specifically designed to target the SARS-CoV-2 spike protein, preventing the virus from entering and infecting human cells. Sotrovimab is used for treating mild-to-moderate COVID-19 in patients at high risk of progressing to severe illness, offering an effective therapeutic option in early-stage infections. For further insights on the Sotrovimab Or Xevudy market, request a sample here

How will the Sotrovimab Or Xevudy market drivers and restraints affect the market dynamics? What forces will shape the Sotrovimab Or Xevudy industry going forward?

The Sotrovimab Or Xevudy market major growth driver - Impact Of Rising COVID-19 Cases On Market Growth. For further insights on the Sotrovimab Or Xevudy market, request a sample here

What is the forecast market size or the forecast market value of the Sotrovimab Or Xevudy market?

The Sotrovimab Or Xevudy market size has grown strongly in recent years. The sotrovimab or xevudy market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to rise in prevalence of COVID-19, the increase in demand for effective monoclonal antibody treatments, growth in awareness of high-risk patient care, rise in government funding, and rise in collaborations between pharmaceutical companies. The sotrovimab or xevudy market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to rising emergence of new COVID-19 variants, increasing focus on monoclonal antibody therapies, expanding healthcare access in developing regions, rising government support for pandemic preparedness, and growing telehealth services for treatment delivery. Major trends in the forecast period include advancements in vaccine manufacturing technologies, innovation in formulations, integration of telehealth, advancements in antibody production technologies, and advancements in antibody engineering. For further insights on the Sotrovimab Or Xevudy market, request a sample here

How is the Sotrovimab Or Xevudy market segmented?

The sotrovimab or xevudy market covered in this report is segmented –
1) By Indication: COVID-19 Early Treatment; Post-Exposure Prophylaxis
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Pediatric; Adult; Geriatric For further insights on the Sotrovimab Or Xevudy market, request a sample here

Which region has the largest share of the Sotrovimab Or Xevudy market? What are the other regions covered in the report?

North America was the largest region in the sotrovimab or xevudy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Sotrovimab Or Xevudy market, request a sample here.

Who are the major players in the Sotrovimab Or Xevudy market?

Major companies operating in the sotrovimab or xevudy market are GSK plc; Vir Biotechnology Inc. . For further insights on the Sotrovimab Or Xevudy market, request a sample here.

What are the key trends in the Sotrovimab Or Xevudy market?

Major trends in the Sotrovimab Or Xevudy market include Strategic Partnerships and Production Expansion in the COVID-19 Treatment Market. For further insights on the Sotrovimab Or Xevudy market, request a sample here.

What are the major opportunities in the Sotrovimab Or Xevudy market? What are the strategies for the Sotrovimab Or Xevudy market?

For detailed insights on the major opportunities and strategies in the Sotrovimab Or Xevudy market, request a sample here.

How does the Sotrovimab Or Xevudy market relate to the overall economy and other similar markets?

For detailed insights on Sotrovimab Or Xevudy's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Sotrovimab Or Xevudy industry?

For detailed insights on the mergers and acquisitions in the Sotrovimab Or Xevudy industry, request a sample here.

What are the key dynamics influencing the Sotrovimab Or Xevudy market growth? SWOT analysis of the Sotrovimab Or Xevudy market.

For detailed insights on the key dynamics influencing the Sotrovimab Or Xevudy market growth and SWOT analysis of the Sotrovimab Or Xevudy industry, request a sample here.